Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

News

News AMERICAN CONSUMER GROUP WARNS AGAINST USE OF OSTEOPOROSIS DRUG The Washington‐based consumer watchdog group, Reuters Health, recently cautioned American consumers against using a new osteoporosis drug named Forteo (Teriparatide). The public citizen advocacy group issued a ‘do not use’ alert in April this year. The alert was based on preclinical studies which allegedly showed that Forteo had led to the formation of bone cancer in some laboratory animals, and also found that higher exposures of the drug seemed to cause faster tumour growth. As a result, the consumer organization concluded that the risks of taking this drug outweigh any clinical benefits. The US Food and Drug Administration (FDA) approved Forteo in November 2002 for treating men and postmenopausal women with osteoporosis, who are assessed as being at high risk of bone fracture. However, Reuters Health states that there is little evidence to show that the drug even reduces the risk of fracture in postmenopausal women, and no data to support the belief that the drug increases bone mass in men with osteoporosis. Following earlier warnings from the consumer group, the FDA did mandate that the drug company place a series of warnings on the drug including what they http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

News

European Journal of Cancer Care , Volume 12 (3) – Sep 1, 2003
Download PDF
5 pages

Loading next page...
 
/lp/wiley/news-uW7Ei4FnGm

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2003 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1046/j.1365-2354.2003.00422.x
Publisher site
See Article on Publisher Site

Abstract

AMERICAN CONSUMER GROUP WARNS AGAINST USE OF OSTEOPOROSIS DRUG The Washington‐based consumer watchdog group, Reuters Health, recently cautioned American consumers against using a new osteoporosis drug named Forteo (Teriparatide). The public citizen advocacy group issued a ‘do not use’ alert in April this year. The alert was based on preclinical studies which allegedly showed that Forteo had led to the formation of bone cancer in some laboratory animals, and also found that higher exposures of the drug seemed to cause faster tumour growth. As a result, the consumer organization concluded that the risks of taking this drug outweigh any clinical benefits. The US Food and Drug Administration (FDA) approved Forteo in November 2002 for treating men and postmenopausal women with osteoporosis, who are assessed as being at high risk of bone fracture. However, Reuters Health states that there is little evidence to show that the drug even reduces the risk of fracture in postmenopausal women, and no data to support the belief that the drug increases bone mass in men with osteoporosis. Following earlier warnings from the consumer group, the FDA did mandate that the drug company place a series of warnings on the drug including what they

Journal

European Journal of Cancer Care – Wiley

Published: Sep 1, 2003

There are no references for this article.